Cargando…
Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
OBJECTIVES: The ovarian tumor marker CA125 is expressed on human MUC16, a cell surface bound mucin that is also shed by proteolytic cleavage. Human MUC16 is overexpressed by ovarian cancer cells. MUC16 facilitates the binding of ovarian tumor cells to mesothelial cells lining the peritoneal cavity....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708168/ https://www.ncbi.nlm.nih.gov/pubmed/19538730 http://dx.doi.org/10.1186/1757-2215-2-8 |
_version_ | 1782169204741373952 |
---|---|
author | Goodell, Cara AR Belisle, Jennifer A Gubbels, Jennifer AA Migneault, Martine Rancourt, Claudine Connor, Joseph Kunnimalaiyaan, Muthusamy Kravitz, Rachel Tucker, Ward Zwick, Michael Patankar, Manish S |
author_facet | Goodell, Cara AR Belisle, Jennifer A Gubbels, Jennifer AA Migneault, Martine Rancourt, Claudine Connor, Joseph Kunnimalaiyaan, Muthusamy Kravitz, Rachel Tucker, Ward Zwick, Michael Patankar, Manish S |
author_sort | Goodell, Cara AR |
collection | PubMed |
description | OBJECTIVES: The ovarian tumor marker CA125 is expressed on human MUC16, a cell surface bound mucin that is also shed by proteolytic cleavage. Human MUC16 is overexpressed by ovarian cancer cells. MUC16 facilitates the binding of ovarian tumor cells to mesothelial cells lining the peritoneal cavity. Additionally, MUC16 also is a potent inhibitor of natural killer cell mediated anti-tumor cytotoxic responses. Extensive studies using human as well as murine ovarian tumor cell models are required to clearly define the function of MUC16 in the progression of ovarian tumors. The major objective of this study was to determine if the murine ovarian tumor cells, MOVCAR, express Muc16 and to characterize antibodies that recognize this mucin. METHODS: RT-PCR analysis was used for detecting the Muc16 message and size exclusion column chromatography for isolating Muc16 produced by MOVCAR cells. Soluble and cell-associated murine Muc16 were analyzed, respectively, by Western blotting and flow cytometry assays using a new panel of antibodies. The presence of N-linked oligosaccharides on murine Muc16 was determined by ConA chromatography. RESULTS: We demonstrate that murine Muc16 is expressed by mouse ovarian cancer cells as an ~250 kDa glycoprotein that carries both O-linked and N-linked oligosaccharides. In contrast to human MUC16, the murine ortholog is primarily released from the cells and cannot be detected on the cell surface. Since the released murine Muc16 is not detected by conventional anti-CA125 assays, we have for the first time identified a panel of anti-human MUC16 antibodies that also recognizes the murine counterpart. CONCLUSION: The antibodies identified in this study can be used in future purification of murine Muc16 and exhaustive study of its properties. Furthermore, the initial identification and characterization of murine Muc16 is a vital preliminary step in the development of effective murine models of human ovarian cancer. These models will aid in the further elucidation of the role that human MUC16 plays in the etiology and progression of ovarian tumors. |
format | Text |
id | pubmed-2708168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27081682009-07-09 Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies Goodell, Cara AR Belisle, Jennifer A Gubbels, Jennifer AA Migneault, Martine Rancourt, Claudine Connor, Joseph Kunnimalaiyaan, Muthusamy Kravitz, Rachel Tucker, Ward Zwick, Michael Patankar, Manish S J Ovarian Res Research OBJECTIVES: The ovarian tumor marker CA125 is expressed on human MUC16, a cell surface bound mucin that is also shed by proteolytic cleavage. Human MUC16 is overexpressed by ovarian cancer cells. MUC16 facilitates the binding of ovarian tumor cells to mesothelial cells lining the peritoneal cavity. Additionally, MUC16 also is a potent inhibitor of natural killer cell mediated anti-tumor cytotoxic responses. Extensive studies using human as well as murine ovarian tumor cell models are required to clearly define the function of MUC16 in the progression of ovarian tumors. The major objective of this study was to determine if the murine ovarian tumor cells, MOVCAR, express Muc16 and to characterize antibodies that recognize this mucin. METHODS: RT-PCR analysis was used for detecting the Muc16 message and size exclusion column chromatography for isolating Muc16 produced by MOVCAR cells. Soluble and cell-associated murine Muc16 were analyzed, respectively, by Western blotting and flow cytometry assays using a new panel of antibodies. The presence of N-linked oligosaccharides on murine Muc16 was determined by ConA chromatography. RESULTS: We demonstrate that murine Muc16 is expressed by mouse ovarian cancer cells as an ~250 kDa glycoprotein that carries both O-linked and N-linked oligosaccharides. In contrast to human MUC16, the murine ortholog is primarily released from the cells and cannot be detected on the cell surface. Since the released murine Muc16 is not detected by conventional anti-CA125 assays, we have for the first time identified a panel of anti-human MUC16 antibodies that also recognizes the murine counterpart. CONCLUSION: The antibodies identified in this study can be used in future purification of murine Muc16 and exhaustive study of its properties. Furthermore, the initial identification and characterization of murine Muc16 is a vital preliminary step in the development of effective murine models of human ovarian cancer. These models will aid in the further elucidation of the role that human MUC16 plays in the etiology and progression of ovarian tumors. BioMed Central 2009-06-18 /pmc/articles/PMC2708168/ /pubmed/19538730 http://dx.doi.org/10.1186/1757-2215-2-8 Text en Copyright © 2009 Goodell et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Goodell, Cara AR Belisle, Jennifer A Gubbels, Jennifer AA Migneault, Martine Rancourt, Claudine Connor, Joseph Kunnimalaiyaan, Muthusamy Kravitz, Rachel Tucker, Ward Zwick, Michael Patankar, Manish S Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
title | Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
title_full | Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
title_fullStr | Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
title_full_unstemmed | Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
title_short | Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
title_sort | characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708168/ https://www.ncbi.nlm.nih.gov/pubmed/19538730 http://dx.doi.org/10.1186/1757-2215-2-8 |
work_keys_str_mv | AT goodellcaraar characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT belislejennifera characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT gubbelsjenniferaa characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT migneaultmartine characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT rancourtclaudine characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT connorjoseph characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT kunnimalaiyaanmuthusamy characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT kravitzrachel characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT tuckerward characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT zwickmichael characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies AT patankarmanishs characterizationofthetumormarkermuc16ca125expressedbymurineovariantumorcelllinesandidentificationofapanelofcrossreactivemonoclonalantibodies |